Amprion, a San Diego, CA-based developer of diagnoses of neurodegenerative disorders, announced an initial $6M closed of a $15M in Series B funding
The round was led by Formation Venture Engineering (FVE) with participation by Eli Lilly and Company and its Series A investors.
The company intends to use the funds to expand its commercial reach and enable increased R&D investment to further enhance brain disease diagnosis.
Led by CEO Russell Lebovitz, Amprion is advancing diagnosis of neurodegenerative disorders through seed amplification testing. The company has evolved seed amplification testing, which enables the detection of small amounts of misfolded proteins in biological samples, such as cerebrospinal fluid (CSF). Amprion’s SAAmplify-ɑSYN biomarker test (formerly SYNTap®) is a validated seed amplification assay that helps with the diagnosis of synucleinopathies associated with Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with neocortical Lewy body co-pathology. The company has also partnered with numerous pharma companies to develop therapies for Parkinson’s disease and other neurodegenerative disorders.
